AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7717559 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.8‐1.2%)
Number of subjects: 20
Study 7717559 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg bolus plus infusion of 150 micrograms.kg‐1.min‐1)
Number of subjects: 20
Study 7717559 — intervention group
Group type: COMPARATOR
Intervention: Baseline anesthesia (thiopental, alfentanil, nitrous oxide, and pancuronium)
Number of subjects: 20
Study 8455371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) with regenerated cellulose
Number of subjects: 12
Study 8455371 — intervention group
Group type: COMPARATOR
Intervention: PBMC re-entering the dialyzer from systemic circulation
Number of subjects: 12
Study 8455371 — intervention group
Group type: COMPARATOR
Intervention: HD using less complement-activating membranes (hemophan, polysulfone, polyamide, polyacrylonitrile)
Number of subjects: 12
Study 8455371 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal antibody against human C5a
Number of subjects: 12
Study 3510384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (125 mg)
Number of subjects: 97
Study 3510384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 97
Study 29326184 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-E You app
Number of subjects: 1400
Study 29326184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1400
Study 26506890 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized treatment strategy based on patient information
Number of subjects: 0
Study 26506890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study data
Number of subjects: 0
Study 25676405 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB) before general anesthesia in group GP
Number of subjects: 40
Study 25676405 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only in group G
Number of subjects: 40
Study 25676405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GP and G)
Number of subjects: 40
Study 23358780 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for daycare teachers
Number of subjects: 96
Study 23358780 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 96
Study 20731585 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied during scaling
Number of subjects: 40
Study 20731585 — intervention group
Group type: COMPARATOR
Intervention: No EMLA cream applied during scaling
Number of subjects: 40
Study 20731585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler used
Number of subjects: 40
Study 20731585 — intervention group
Group type: COMPARATOR
Intervention: Gracey curet used
Number of subjects: 40
Study 19902797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplement of 40 mg of zinc as zinc gluconate and 40 mg of iron as ferrous sulphate
Number of subjects: 600
Study 19902797 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of elemental iron as ferrous sulphate
Number of subjects: 600
Study 16517274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal protein D conjugate
Number of subjects: 4968
Study 16517274 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Control)
Number of subjects: 4968
Study 15297105 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil
Number of subjects: 20
Study 15297105 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil
Number of subjects: 20
Study 10664922 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg bid, escalated to 30 mg bid, then to 40 mg bid
Number of subjects: 12
Study 10664922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9881555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and trabeculectomy (phaco-trab)
Number of subjects: 20
Study 9881555 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification (phaco)
Number of subjects: 20
Study 7817443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (short-term intensive weekly instillation)
Number of subjects: 333
Study 7817443 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (3-year protocol)
Number of subjects: 333
Study 7817443 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin regimen
Number of subjects: 333
Study 7817443 — intervention group
Group type: COMPARATOR
Intervention: Combination of short-term and 3-year protocols
Number of subjects: 333
Study 3041327 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg i.m.)
Number of subjects: 36
Study 3041327 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein (5 micrograms i.m.)
Number of subjects: 36
Study 30364350 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment (n = 7)
Number of subjects: 29
Study 27661192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 IU)
Number of subjects: 17
Study 27661192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline nasal spray)
Number of subjects: 17
Study 24398722 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS)
Number of subjects: 16
Study 24398722 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (S-tDCS)
Number of subjects: 16
Study 22738803 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety closed IV catheter system (BD Pegasus*)
Number of subjects: 257
Study 22738803 — intervention group
Group type: COMPARATOR
Intervention: Non-safety device (BD Intima II)
Number of subjects: 257
Study 21081801 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan 500 mg twice daily and Essentiale forte 3 times a day for 4 weeks
Number of subjects: 45
Study 21081801 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg twice a day and Essentiale forte 3 times a day for 4 weeks
Number of subjects: 45
Study 21081801 — intervention group
Group type: COMPARATOR
Intervention: Essentiale forte with placebo 3 times a day for 4 weeks
Number of subjects: 45
Study 18759317 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized rheumatology nurse (SRN) group, n = 97
Number of subjects: 193
Study 18759317 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist (RMT) group, n = 96
Number of subjects: 193
Study 16198932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.8 g/kg/day)
Number of subjects: 63
Study 16198932 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 63
Study 12456423 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine 4 mg (Group N)
Number of subjects: 124
Study 12456423 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.625 mg plus nalbuphine 4 mg (Group ND)
Number of subjects: 124
Study 9550507 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased oxygen extraction fraction (OEF) in patients with prior ischemic symptoms
Number of subjects: 117
Study 9550507 — intervention group
Group type: COMPARATOR
Intervention: Normal oxygen extraction fraction (OEF) in asymptomatic patients
Number of subjects: 117
Study 2569323 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription Information Leaflets (PILs) distributed by pharmacists or general practitioners
Number of subjects: 719
Study 2569323 — intervention group
Group type: COMPARATOR
Intervention: No Prescription Information Leaflets (Control)
Number of subjects: 719
Study 770552 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin challenge
Number of subjects: 50
Study 770552 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind protocol
Number of subjects: 50
Study 29957680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received a brochure and an outreach telephone call.
Number of subjects: 115
Study 29957680 — intervention group
Group type: COMPARATOR
Intervention: Control group received no active outreach.
Number of subjects: 115
Study 29957680 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outreach for intervention group.
Number of subjects: 115
Study 29957680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group ratings of communication and support for speaking up.
Number of subjects: 115
Study 31132980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet rich in omega-3 (n=18)
Number of subjects: 54
Study 31132980 — intervention group
Group type: COMPARATOR
Intervention: Lacto-ovo-vegetarian diet rich in EVO (n=22)
Number of subjects: 54
Study 28736309 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program aimed at improving cognitive control
Number of subjects: 0
Study 28736309 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 28736309 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program
Number of subjects: 0
Study 25803783 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA and arginine supplementation (0.17 g/kg BCAA and 0.04 g/kg arginine)
Number of subjects: 22
Study 25803783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB trial)
Number of subjects: 22
Study 24063176 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL retaining group (group A)
Number of subjects: 38
Study 24063176 — intervention group
Group type: COMPARATOR
Intervention: PCL substituting group (group B)
Number of subjects: 38
Study 24063176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 38
Study 21327794 — intervention group
Group type: EXPERIMENTAL
Intervention: L + A (leg exercises before elbow flexor training)
Number of subjects: 9
Study 21327794 — intervention group
Group type: COMPARATOR
Intervention: A (arm training without prior leg exercises)
Number of subjects: 9
Study 19739491 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched formula (Kcal: 75/100 ml, proteins: 2 g/100 ml)
Number of subjects: 27
Study 19739491 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (Kcal: 67/100 ml, proteins: 1.4 g/100 ml)
Number of subjects: 27
Study 17766511 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 194
Study 15037328 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily
Number of subjects: 1123
Study 15037328 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg once daily
Number of subjects: 1123
Study 15037328 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 1123
Study 11319653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day) with a low-fat low-energy individualized diet (600 kcal/day deficit)
Number of subjects: 605
Study 11319653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 605
Study 11319653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 9874862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (10 micrograms) added to 12.5 mg of 0.5% bupivacaine
Number of subjects: 41
Study 9874862 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine alone (Control group)
Number of subjects: 41
Study 7857761 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 7857761 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (enalapril, captopril)
Number of subjects: 0
Study 7857761 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade
Number of subjects: 0
Study 7857761 — intervention group
Group type: COMPARATOR
Intervention: Cardiac glycosides
Number of subjects: 0
Study 3168937 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (Niopam)
Number of subjects: 85
Study 3168937 — intervention group
Group type: COMPARATOR
Intervention: Urografin (meglumine diatrizoate)
Number of subjects: 85
Study 348532 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 0
Study 348532 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 600 mg
Number of subjects: 0
Study 348532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 348532 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 125 mg
Number of subjects: 0
Study 348532 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg
Number of subjects: 0
Study 31668721 — intervention group
Group type: COMPARATOR
Intervention: 1.5 L of Sterofundin ISO (Reference arm A)
Number of subjects: 12
Study 31668721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 L of 4% Gelaspan® (Isoeffective arm B)
Number of subjects: 12
Study 31668721 — intervention group
Group type: COMPARATOR
Intervention: 0.5 L of 4% Gelaspan® and 1 L of Sterofundin ISO (Isovolumetric arm C)
Number of subjects: 12
Study 31163434 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid 1,000 mg
Number of subjects: 411
Study 31163434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 29019886 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 62
Study 29019886 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 25845864 — intervention group
Group type: EXPERIMENTAL
Intervention: delafloxacin 300 mg i.v. (therapeutic)
Number of subjects: 52
Study 25845864 — intervention group
Group type: EXPERIMENTAL
Intervention: delafloxacin 900 mg i.v. (supratherapeutic)
Number of subjects: 52
Study 25845864 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin 400 mg orally (positive control)
Number of subjects: 52
Study 25845864 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study 24158584 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 62
Study 24158584 — intervention group
Group type: COMPARATOR
Intervention: Monitored group (no further treatment)
Number of subjects: 62
Study 22264450 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatinose™
Number of subjects: 20
Study 22264450 — intervention group
Group type: COMPARATOR
Intervention: glucose syrup/sucrose (glc/suc)
Number of subjects: 20
Study 19932541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, 20 mg/d
Number of subjects: 304
Study 19932541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 17088036 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel containing 5% of a crude extract standardized in its tannin concentration (1.8%)
Number of subjects: 0
Study 17088036 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel without addition of the extract (Control)
Number of subjects: 0
Study 16305977 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 20 mg/day
Number of subjects: 203
Study 16305977 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 10 mg/day plus valsartan 80 mg/day
Number of subjects: 203
Study 16305977 — intervention group
Group type: COMPARATOR
Intervention: valsartan 160 mg/day
Number of subjects: 203
Study 12193905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 23
Study 12193905 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 23
Study 9862607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 9862607 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 9862607 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondepressed community sample)
Number of subjects: 0
Study 9862607 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with full symptomatic response (remission)
Number of subjects: 0
Study 8700610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton ball method
Number of subjects: 30
Study 8700610 — intervention group
Group type: COMPARATOR
Intervention: Preemie Pampers
Number of subjects: 30
Study 8700610 — intervention group
Group type: COMPARATOR
Intervention: Newborn Pampers
Number of subjects: 30
Study 8700610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton ball and catheterization
Number of subjects: 30
Study 2496173 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg every 4 hours)
Number of subjects: 29
Study 2496173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2496173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (800 mg or 600 mg daily)
Number of subjects: 29
Study 710312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (3 X 5000 IU/24 h)
Number of subjects: 113
Study 710312 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-dose heparin and acetylsalicyl-lysine (given intravenously)
Number of subjects: 113
Study 710312 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased heparin dosage (3 X 7500 IU/24 h)
Number of subjects: 113
Study 710312 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving any heparin)
Number of subjects: 113
Study 31414266 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based weight-loss treatment for children with ASD (PBT-ASD)
Number of subjects: 20
Study 28809770 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based paired syphilis and HIV testing during pregnancy
Number of subjects: 310
Study 28809770 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based paired syphilis and HIV testing postpartum
Number of subjects: 310
Study 28809770 — intervention group
Group type: COMPARATOR
Intervention: HIV testing before syphilis test introduction
Number of subjects: 310
Study 28809770 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing with paired testing offered
Number of subjects: 310
Study 25730000 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (kidney-reinforcing and blood-activating), N = 35
Number of subjects: 70
Study 25730000 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (Control), N = 35
Number of subjects: 70
Study 23618450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 session daily (OD)
Number of subjects: 145
Study 23618450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 session weekly with optional deliberate practice (WD)
Number of subjects: 145
Study 23618450 — intervention group
Group type: COMPARATOR
Intervention: 1 session weekly (C)
Number of subjects: 145
Study 23618450 — intervention group
Group type: COMPARATOR
Intervention: 3 sessions daily (TD)
Number of subjects: 145
Study 21067912 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and magnesium infusions (Ca/Mg(+))
Number of subjects: 732
Study 21067912 — intervention group
Group type: COMPARATOR
Intervention: No calcium and magnesium infusions (Ca/Mg(-))
Number of subjects: 732
Study 20108552 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.02%
Number of subjects: 26
Study 20108552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16700640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Stress Management (CBSM) intervention
Number of subjects: 191
Study 16700640 — intervention group
Group type: COMPARATOR
Intervention: Half-day educational seminar (Control)
Number of subjects: 191
Study 15001406 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Pain Scores (VPS)
Number of subjects: 150
Study 15001406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean time to analgesic administration
Number of subjects: 150
Study 11315920 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus medroxy progesterone acetate (hormone therapy)
Number of subjects: 969
Study 11315920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 969
Study 9278766 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + HT
Number of subjects: 101
Study 9278766 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 101
Study 9278766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative minimum thermal isoeffect dose (equivalent minutes at 43 degrees C)
Number of subjects: 101
Study 9278766 — intervention group
Group type: EXPERIMENTAL
Intervention: MINTIME > 42 degrees C (first treatment session)
Number of subjects: 101
Study 9278766 — intervention group
Group type: EXPERIMENTAL
Intervention: %sensors > 43 degrees C (peak, second treatment session)
Number of subjects: 101
Study 8315435 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (50 x 10(6) U/m2 intramuscularly three times per week)
Number of subjects: 159
Study 8315435 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (gradually escalating doses from 3 to 36 x 10(6) U subcutaneously administered daily)
Number of subjects: 159
Study 8315435 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (daily)
Number of subjects: 159
Study 8315435 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (daily) + vinblastine (0.15 mg/kg every 3 weeks)
Number of subjects: 159
Study 8315435 — intervention group
Group type: COMPARATOR
Intervention: Control group (vinblastine only)
Number of subjects: 159
Study 3099564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg BID
Number of subjects: 8
Study 3099564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg HS
Number of subjects: 8
Study 3099564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg HS
Number of subjects: 8
Study 3099564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3099564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg HS (nonrandomized)
Number of subjects: 8
Study 30287607 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide forced diuresis with matched hydration using the RenalGuard system
Number of subjects: 0
Study 30287607 — intervention group
Group type: COMPARATOR
Intervention: Standard of care prehydration and posthydration
Number of subjects: 0
Study 27646578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) alone (1.9 g DHA + EPA/day)
Number of subjects: 89
Study 27646578 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG alone (600 mg/day)
Number of subjects: 89
Study 27646578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FO and EGCG
Number of subjects: 89
Study 27646578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 25039111 — intervention group
Group type: EXPERIMENTAL
Intervention: Child abuse history (abused girls)
Number of subjects: 84